Male urogenital tract mycoplasma infection and drug-resistance evolution / 中华男科学杂志

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the male urogenital tract mycoplasma infection and drug-resistance evolution in 2001 and 2003.</p><p><b>METHODS</b>The results of mycoplasma culture and drug sensitivity tests were explored in 2001 and 2003, and the differences of drug sensitivity between the two years were analysed.</p><p><b>RESULTS</b>Of the 109 mycoplasma positive cases in 2001, 86.2% were infected with Ureaplasma urealyticum (Uu), 3.8% with Mycoplasma hominis (Mh), 10.1% with both Uu and Mh; and of the 134 mycoplasma positive cases in 2003, Uu infection accounted for 79.1%, Mh infection 4.48% and Uu and Mh infection 16.4%. Compared with 2001, the drug-resistance rates to roxithromycin, azithromycin, levofloxacin, ofloxacin and clindamycin rose obviously in 2003; but the drug-resistance rates to josamycin, minomycin and doxycycline did not change significantly. As far as the drug sensitivity rate is concerned, josamycin ranked the first, and doxycycline the second.</p><p><b>CONCLUSIONS</b>Mycoplasma was a high rate of drug-resistance, and the drug sensitivity evolves with the time. Treatment for mycoplasma should be based on the results of drug sensitivity tests. Josamycin can be used as the first choice.</p>